(Boursier.com) — The Company Theravet generated a turnover of €0.12 million in 2023, of which approximately 75% was in Europe. In total, 741 units of the BIOCERA-VET range have been sold. If the BIOCERA-VET BONE SURGERY range still represents 80% of total sales, up 50% compared to 2022, BIOCERA-VET OSTEOSARCOMA shows strong growth in 2023, with an increase of almost 70% compared to 2022, highlighting the interest generated by this unique solution for the management of osteosarcoma in dogs. In the United States, sales, solely from direct sales, accelerated in 2023, with 173 units sold, an increase by 5.7.
The Company also records 0.96 ME of capitalized production following the activation of research and development expenses linked to the BIOCERA-VET(R) and VISCO VET programs.
Personnel costs decreased by €0.35 million compared to 2022, an equally significant reduction of 32%, due to the Company’s ongoing organizational efficiency initiatives. Finally, the amortization of development costs linked to the BIOCERA-VET and VISCOVET programs results in an operational loss of 2.2 ME and a net loss of 1.6 ME.
As of December 31, 2023, the company’s cash position amounted to €1.15 million, covering the financing of the activity until at least November 2024.
©2024 Boursier.com